Emerging combinatorial hormone therapies for the treatment of obesity and T2DM. (Q38088108)

28 August 2017

Emerging combinatorial hormone therapies for the treatment of obesity and T2DM. (English)

1 reference

28 August 2017

0 references

2

Daniel J Drucker

1 reference

28 August 2017

Sharon A Sadry

1

1 reference

28 August 2017

12 March 2013

1 reference

Nature Reviews Endocrinology

28 August 2017

1 reference

28 August 2017

9

1 reference

28 August 2017

7

1 reference

28 August 2017

425-433

1 reference

https://scigraph.springernature.com/pub.10.1038/nrendo.2013.47

28 August 2017

0 references

cites work

Bariatric surgery and long-term cardiovascular events.

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.47

Pharmacology, physiology, and mechanisms of incretin hormone action

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.47

Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.47

Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.47

The FDA's assessment of two drugs for chronic weight management

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.47

Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.47

The metabolic actions of glucagon revisited

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.47

Hyperglucagonemia increases resting metabolic rate in man during insulin deficiency

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.47

Coadministration of glucagon-like peptide-1 during glucagon infusion in humans results in increased energy expenditure and amelioration of hyperglycemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.47

Effects of glucagon on lipolysis and ketogenesis in normal and diabetic men

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.47

Effect of low glycogen on carbohydrate and energy metabolism in human muscle during exercise

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.47

Fibroblast growth factor 21 mediates specific glucagon actions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.47

Endocrine fibroblast growth factors 15/19 and 21: from feast to famine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.47

The biology of incretin hormones

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.47

The inhibitory effects of peripheral administration of peptide YY(3-36) and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal-brainstem-hypothalamic pathway

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.47

The diverse roles of specific GLP-1 receptors in the control of food intake and the response to visceral illness

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.47

An albumin-exendin-4 conjugate engages central and peripheral circuits regulating murine energy and glucose homeostasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.47

Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.47

Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.47

Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.47

A role for glucagon-like peptide-1 in the central regulation of feeding

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.47

A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.47

Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.47

International Union of Pharmacology. XXXV. The glucagon receptor family

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.47

Oxyntomodulin inhibits food intake in the rat

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.47

Peripheral oxyntomodulin reduces food intake and body weight gain in rats.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.47

Direct control of brown adipose tissue thermogenesis by central nervous system glucagon-like peptide-1 receptor signaling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.47

The glucagon receptor is involved in mediating the body weight-lowering effects of oxyntomodulin.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.47

Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.47

Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.47

Glucagon and GLP-1 inhibit food intake and increase c-fos expression in similar appetite regulating centres in the brainstem and amygdala

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.47

A new glucagon and GLP-1 co-agonist eliminates obesity in rodents

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.47

Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.47

Differential effects of oxyntomodulin and GLP-1 on glucose metabolism

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.47

Biology of incretins: GLP-1 and GIP

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.47

Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.47

Extrapancreatic incretin receptors modulate glucose homeostasis, body weight, and energy expenditure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.47

Exogenous glucose-dependent insulinotropic polypeptide worsens post prandial hyperglycemia in type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.47

GIP: no longer the neglected incretin twin?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.47

Differential antidiabetic efficacy of incretin agonists versus DPP-4 inhibition in high fat fed mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.47

Antidiabetic effects of sub-chronic activation of the GIP receptor alone and in combination with background exendin-4 therapy in high fat fed mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.47

Administration of an acylated GLP-1 and GIP preparation provides added beneficial glucose-lowering and insulinotropic actions over single incretins in mice with Type 2 diabetes and obesity.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.47

Metabolic effects of sustained activation of the GLP-1 receptor alone and in combination with background GIP receptor antagonism in high fat-fed mice.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.47

Comparison of independent and combined chronic metabolic effects of GIP and CB1 receptor blockade in high-fat fed mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.47

Outstanding Scientific Achievement Award Lecture 2011: defeating diabesity: the case for personalized combinatorial therapies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.47

GIP does not potentiate the antidiabetic effects of GLP-1 in hyperglycemic patients with type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.47

Pancreatic gastrin stimulates islet differentiation of transforming growth factor alpha-induced ductular precursor cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.47

Gastrin stimulates beta-cell neogenesis and increases islet mass from transdifferentiated but not from normal exocrine pancreas tissue

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.47

Combination therapy with glucagon-like peptide-1 and gastrin restores normoglycemia in diabetic NOD mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.47

The novel GLP-1-gastrin dual agonist, ZP3022, increases β-cell mass and prevents diabetes in db/db mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.47

Pantoprazole improves glycemic control in type 2 diabetes: a randomized, double-blind, placebo-controlled trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.47

Effects of 12 weeks' treatment with a proton pump inhibitor on insulin secretion, glucose metabolism and markers of cardiovascular risk in patients with type 2 diabetes: a randomised double-blind prospective placebo-controlled study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.47

Amylin and the regulation of appetite and adiposity: recent advances in receptor signaling, neurobiology and pharmacology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.47

Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.47

Challenges and opportunities of defining clinical leptin resistance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.47

Leptin revisited: its mechanism of action and potential for treating diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.47

Modulation of the satiating effect of amylin by central ghrelin, leptin and insulin.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.47

Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.47

Effects of leptin replacement alone and with exendin-4 on food intake and weight regain in weight-reduced diet-induced obese rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.47

Restoration of leptin responsiveness in diet-induced obese mice using an optimized leptin analog in combination with exendin-4 or FGF21

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.47

Amylin-mediated restoration of leptin responsiveness in diet-induced obesity: magnitude and mechanisms

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.47

Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.47

Neuropeptide Y, peptide YY and pancreatic polypeptide in the gut-brain axis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.47

Effects of peptide YY (PYY) on mouth to caecum intestinal transit time and on the rate of gastric emptying in healthy volunteers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.47

Inhibition of food intake in obese subjects by peptide YY3-36

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.47

Efficacy and safety of intranasal peptide YY3-36 for weight reduction in obese adults

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.47

Combination therapy with amylin and peptide YY[3-36] in obese rodents: anorexigenic synergy and weight loss additivity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.47

Fibroblast growth factor 21 promotes bone loss by potentiating the effects of peroxisome proliferator-activated receptor γ.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.47

Glucagon and a glucagon-GLP-1 dual-agonist increases cardiac performance with different metabolic effects in insulin-resistant hearts.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.47

Cardiovascular biology of the incretin system

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.47

The safety of incretin-based therapies--review of the scientific evidence

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.47

Effects of amylin and bupropion/naltrexone on food intake and body weight are interactive in rodent models

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.47

Oxyntomodulin and glicentin: brain-gut peptides in the rat

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.47

Individual, but not simultaneous, glucagon and cholecystokinin infusions inhibit feeding in men

31 March 2020

1 reference

12 December 2020

Glucagon gene expression in vertebrate brain

1 reference

12 December 2020

Comparison of the independent and combined metabolic effects of subchronic modulation of CCK and GIP receptor action in obesity-related diabetes

1 reference

12 December 2020

Mixed chimerism and growth factors augment β cell regeneration and reverse late-stage type 1 diabetes.

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRENDO.2013.47

1 reference

release_oebpyfiinvhsff7guxcox5smoa

28 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/oebpyfiinvhsff7guxcox5smoa

24 November 2022

mapped directly with Wikidata item

PubMed ID

23478327

1 reference

PubMed ID

23478327